Website Search
Find information on spaces, staff, and services.
Catalog Search
Videos, Slides, Films
Papillomaviruses and HPV vaccination to prevent cervical cancer and other HPV-associated diseases
- Author / Creator
- Available as
- Online
- Summary
-
Audio-visual presentation : Cervical cancer is attributable to multiple HPV types; HPV16 predominates ; Cervical cancer: time line of cervical HPV infections, progression and natural history ; Key ...
Audio-visual presentation : Cervical cancer is attributable to multiple HPV types; HPV16 predominates ; Cervical cancer: time line of cervical HPV infections, progression and natural history ; Key features of HPV pathogenesis ; Challenges to development of a preventive HPV vaccine ; A prophylactic vaccine ; Formation of papillomavirus virions ; Two distinct HPV VLP vaccines are under commercial development ; Partial crossprotection against incident infection by other high risk HPV types ; Overall efficacy in preventing HPV cervical disease attributable to incident infection ; HPV life cycle ; How could IM injection of a VLP vaccine prevent mucosal or cutaneous infection at the cervix? ; Outstanding medical issues ; Regulatory status of HPV VLP vaccines ; Pap smear screening without vaccination would prevent more cervical cancer deaths than HPV16/18 vaccination without pap screening ; Limitations of current VLP vaccines.
Details
- Creator
- Doug Lowy
- Format
- Videos, Slides, Films
- Language
- English
- Publication
-
- London : Henry Stewart Talks Ltd, 2007
- Physical Details
-
- 1 videorecording (31 min., 28 sec.)
- video file
- Retrieved April 16, 2024, from https://hstalks.com/bs/369/.
- Introduction -- Disclosure -- Outline of presentation -- Cancers attributable to HPV infection -- HPV types associated with cervical cancer -- Progression of cervical HPV infections to cancer -- Natural history of cervical HPV infection -- Key features of HPV pathogenesis -- Genital warts -- Laboratory of cellular oncology, CCR, NCI -- Developing preventive HPV vaccine challenges -- A prophylactic vaccine -- Formation of papillomavirus virions -- L1 self-assembles to form virus-like particles -- L1 VLP induction of neutralizing antibodies -- Systemic VLP vaccination in animal models -- Two HPV VLP vaccines are under development -- Merck: phase III prophylactic efficacy results -- Possible long term protection by HPV vaccine -- Cross-protection against other HPV types -- Preventing HPV cervical disease efficacy -- HPV life cycle -- How could vaccine prevent mucosal infection -- How could vaccine prevent cutaneous infection -- L1 VLPs are unlikely to be directly therapeutic -- Will the vaccines influence prevalent infection? -- Outstanding medical issues -- Regulatory status of HPV VLP vaccines -- Gardasil phase III adolescent study -- Percentage of sexually active teenagers in USA -- Disease progression by HPV status at entry -- We can't give up screening -- Cervical cancer prevention by Pap screening -- HPV-based cervical cancer prevention strategy -- HPV vaccination in developing nations -- Limitations of current VLP vaccines -- Potential reduction in cervical cancer -- Papillomaviruses neutralized by BPV1 L2 -- Vaccination with L1-Salmonella live vaccine -- Summary and conclusions